-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $402

Benzinga·11/05/2026 22:23:12
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $397 to $402.